Several of the women in the study were experiencing symptoms associated with fibroids, endometriosis or menstrual complaints when enrolled into the trial. Entering the trial, 8 of the 11 women that completed the study complained of symptoms associated with either endometriosis, uterine fibroids, excessive menstrual bleeding or painful menses. Of these 8 women, 5 reported improvement in their symptoms following the 10 week study. When these assessments were compared to the placebo phase of the trial using a simple symptom severity questionnaire, a solid trend towards statistical significance in symptom improvement was seen, p=0.11. Key symptoms associated with uterine fibroids and endometriosis are, excessive menstrual bleeding and bulk related symptoms for fibroids and menstrual and pelvic pain for endometriosis.
Joseph S. Podolski, President and CEO of Repros noted, "These findings have exceeded our expectations. We eagerly look forward to the higher dose cohorts to see if these findings are enhanced in a dose dependent manner."
The Company plans to issue similar releases as each new cohort completes dosing. Repros believes the study can be completed during the fourth quarter of 2011.
About Repros Therapeutics Inc.Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. The Repros Therapeutics Inc. logo is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=7738 Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have the partial hold on Proellex ® lifted, the reliability of preliminary data and interim results, whether a safe and effective dose for Proellex can be determined, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information, please visit the Company's website at http://www.reprosrx.com .
CONTACT: Repros Therapeutics Inc. Joseph Podolski (281) 719-3447 President and Chief Executive Officer
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV